Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

Iris E. Beldhuis, Carolyn S. P. Lam, Jeffrey M. Testani, Adriaan A. Voors, Harriette G. C. Van Spall, Jozine M. ter Maaten, Kevin Damman*

*Corresponding author voor dit werk

Onderzoeksoutput: ArticleAcademicpeer review

101 Citaten (Scopus)
441 Downloads (Pure)

Samenvatting

Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate (eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction (HFrEF). The presence of CKD is associated with more severe heart failure, and CKD itself is a strong independent risk factor of poor cardiovascular outcome. Furthermore, the presence of CKD often influences the decision to start, uptitrate, or discontinue possible life-saving HFrEF therapies. Because pivotal HFrEF randomized clinical trials have historically excluded patients with stage 4 and 5 CKD (eGFR

Originele taal-2English
Pagina's (van-tot)693-712
Aantal pagina's20
TijdschriftCirculation
Volume145
Nummer van het tijdschrift9
DOI's
StatusPublished - 1-mrt.-2022

Vingerafdruk

Duik in de onderzoeksthema's van 'Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease'. Samen vormen ze een unieke vingerafdruk.

Citeer dit